Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223373 · ClinicalTrials.gov registry record · NA
Blood Flow Restriction Therapy Following Acute Shoulder Injury Patients
A NA study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT06223373 is a NA study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 3 participants.
The verdict
NCT06223373, a NA study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Atrophy and weakness of the shoulder are a common problem following treatment of a number of shoulder and elbow pathologies. Even with relatively short periods of reduced activity, the magnitude of muscle loss can be quite substantial.
Interventions
- DEVICE Blood Flow Restriction
- DEVICE "sham" Blood Flow Restriction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-04-13 |
| Est. Completion | 2024-10-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06223373
The ClinicalTrials.gov registry entry for NCT06223373 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood Flow Restriction is the first listed.
NCT06223373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06223373 about?
NCT06223373 is a clinical study titled "Blood Flow Restriction Therapy Following Acute Shoulder Injury Patients". Atrophy and weakness of the shoulder are a common problem following treatment of a number of shoulder and elbow pathologies. Even with relatively short periods of reduced activity, the magnitude of muscle loss can be quite substantial.
What is the current status of trial NCT06223373?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2024-04-13. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT06223373?
The interventions under investigation include: Blood Flow Restriction (DEVICE), "sham" Blood Flow Restriction (DEVICE).
Who is sponsoring clinical trial NCT06223373?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.